Ascendis Pharma A/S

Ascendis Pharma A/S is a global biopharmaceutical company headquartered in Hellerup, Denmark, focused on developing innovative therapies for serious diseases. The company's core mission is to apply its proprietary TransCon technology platform to create new and potentially best-in-class treatments that address significant unmet medical needs, thereby making a meaningful difference in patients' lives.

Ascendis Pharma leverages its TransCon (transient conjugation) technology to develop long-acting prodrugs designed for sustained release of active drugs, aiming to improve efficacy, tolerability, and patient convenience. The company's key products include SKYTROFA (lonapegsomatropin) for pediatric growth hormone deficiency, YORVIPATH (palopegteriparatide) for adult hypoparathyroidism, and YUVIWEL (navepegritide) for achondroplasia. Its pipeline and market segments primarily focus on endocrinology rare diseases and are expanding into oncology.

Under the leadership of President and CEO Jan Møller Mikkelsen, Ascendis Pharma is rapidly transitioning into a commercial-stage biopharmaceutical company. The company reported full-year 2025 product revenue of €684 million. Recent notable developments include the FDA Priority Review for TransCon CNP (YUVIWEL) with a PDUFA date of February 28, 2026, and its subsequent launch in April 2026. In April 2026, Ascendis Pharma also announced the commencement of trading of its ordinary shares directly on Nasdaq. The company aims to achieve blockbuster status for multiple products and expand its innovation engine by 2030.